Cutia Therapeutics (HKSE:02487) Net Margin % : -4,776.30% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cutia Therapeutics's Net Income for the six months ended in Jun. 2023 was HK$-1,794.2 Mil. Cutia Therapeutics's Revenue for the six months ended in Jun. 2023 was HK$37.6 Mil. Therefore, Cutia Therapeutics's net margin for the quarter that ended in Jun. 2023 was -4,776.30%.

The historical rank and industry rank for Cutia Therapeutics's Net Margin % or its related term are showing as below:

HKSE:02487' s Net Margin % Range Over the Past 10 Years
Min: -15684.05 Med: -10287.12 Max: -1426.91
Current: -1426.91

HKSE:02487's Net Margin % is ranked worse than
77.41% of 1027 companies
in the Biotechnology industry
Industry Median: -151.78 vs HKSE:02487: -1426.91

Cutia Therapeutics Net Margin % Historical Data

The historical data trend for Cutia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Net Margin % Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Net Margin %

-15,684.05

-4,890.18

-1,426.91

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	-	-38,254.22	-2,841.03	-4,776.30	-313.15

Competitive Comparison of Cutia Therapeutics's Net Margin %

For the Biotechnology subindustry, Cutia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cutia Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Net Margin % falls into.

Cutia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cutia Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-620.71	/	12.693
	=	-4,890.18 %

Cutia Therapeutics's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1794.171	/	37.564
	=	-4,776.30 %

Cutia Therapeutics (HKSE:02487) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Cutia Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics (HKSE:02487) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.

Executives

Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hsg Holding Limited	2201 Interest of corporation controlled by you
Ma Yun	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Aurora Cutis Limited	2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines